ArticleNature2026
Thymic health and immunotherapy outcomes in patients with cancer.
Abstract read
In one paragraph
Article in Nature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Naive T cell decline limits cancer immunity in middle-aged male mice.Nature aging · 2026Article
- Lymph node contraction links sex-biased naive CD8Nature aging · 2026Article
- Breast cancer immunogenicity as a spectrum: evolving concepts and therapeutic implications.The Journal of clinical investigation · 2026Review
- Thymic function as a central determinant of immune competence and clinical outcomes.Seminars in immunopathology · 2026Review
- Toward precision adjuvant immunotherapy in high-risk clear cell renal cell carcinoma: integrating plasma multiomics with PD-1 blockade.Journal for immunotherapy of cancer · 2026Article
- Why Some People Live Past 100: The Role of the Immune System in Centenarians, Semi-Supercentenarians and Supercentenarians.International journal of molecular sciences · 2026Review
- Thymic health and implications for chronic kidney disease.Nature reviews. Nephrology · 2026Article
- The Thymic Microenvironment Shapes Age-Related Qualitative Changes in the TCR Repertoire.Aging cell · 2026Article
- Analysis of Human Thymopoiesis Reveals Rapid Postnatal Remodeling of Thymocytes Within the First 3 Months of Life.European journal of immunology · 2026Article
- Long-Term Cancer and Mortality After Thymectomy.European journal of neurology · 2026Article
- Thymulin restrains age-associated myeloid inflammation and enhances cancer immunotherapy.Nature communications · 2026Article
- Article
- Guarding epithelial integrity: origins of adaptive immunity and cancer immunosurveillance over time and space.Journal for immunotherapy of cancer · 2026Review
- Aging diminishes thymic output, reduces naive T cells, promotes memory T-cell accumulation, and impairs thymic regeneration.American journal of physiology. Regulatory, integrative and comparative physiology · 2026Article
- Immunological Drug-Drug Interactions in Immune Checkpoint Inhibitor Therapy: Mechanisms, Clinical Evidence, and Artificial Intelligence.Current oncology reports · 2026Review
- Senescence of T cells and organ aging.Inflammation and regeneration · 2026Review
- Article
- Mechanism and intervention strategy of thymus atrophy in cancer immunotherapy.American journal of cancer research · 2026Review
- Network-orchestrated regulation of thymic dysfunction and restoration.Frontiers in immunology · 2026Review
- Inhibitory receptor states, immune homeostasis and the benefit-risk boundary of cancer checkpoint blockade.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Simon Bernatz *Artificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-7758-8100
Vasco Prudente *Artificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0003-0623-1259
Suraj Pai *Artificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Harvard Medical School, Boston, MA, USA.
Asbjørn K Attermann *Artificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0009-0006-3307-0031
Alessandro Di FedericoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Andrew RowanCancer Evolution and Genome Instability Laboratory, Francis Crick Institute, London, UK.
Selvaraju VeeriahCancer Evolution and Genome Instability Laboratory, Francis Crick Institute, London, UK.
Lars DyrskjøtDepartment of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.ORCID http://orcid.org/0000-0001-7061-9851
Leonard NürnbergArtificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-6544-4268
Joao V AlessiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Patrick A OttDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-4253-943X
Elad SharonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Allan HackshawCancer Research UK and UCL Cancer Trials Centre, London, UK.ORCID http://orcid.org/0000-0002-5570-5070
Nicholas McGranahanCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0001-9537-4045
Christopher AbboshCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0002-8983-1382
Raymond H MakArtificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-8754-0565
Danielle BittermanArtificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Harvard Medical School, Boston, MA, USA.
Mark AwadDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Biagio RicciutiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Charles SwantonCancer Evolution and Genome Instability Laboratory, Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0002-4299-3018
Mariam Jamal-HanjaniCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0003-1212-1259
Nicolai J BirkbakDepartment of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.ORCID http://orcid.org/0000-0003-1613-9587
Hugo J W L AertsArtificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Harvard Medical School, Boston, MA, USA. haerts@bwh.harvard.edu.ORCID http://orcid.org/0000-0002-2122-2003
Funding
The Boston Lung Cancer Survival CohortU01CA209414 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI David C Christiani · 2017 to 2026
$12.2MUnraveling the Complexities of Risk and Mechanism in CancerR35CA220523 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI QUACKENBUSH, JOHN · 2018 to 2024
$6.0MQuantitative Radiomics System Decoding the Tumor PhenotypeU24CA194354 · NCI · DANA-FARBER CANCER INST · PI AERTS, HUGO, QUACKENBUSH, JOHN · 2015 to 2019
$3.5MGenotype and Imaging Phenotype Biomarkers in Lung CancerU01CA190234 · NCI · DANA-FARBER CANCER INST · PI AERTS, HUGO, QUACKENBUSH, JOHN · 2015 to 2019
$3.3MInformatics strategies to improve immune-related adverse event detection in cancer patientsR01CA294033 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Hugo Aerts · 2024 to 2026
$1.3MNCI NIH HHS R01 CA294033NCI NIH HHS R35 CA220523NCI NIH HHS U01 CA190234NCI NIH HHS U01 CA209414NCI NIH HHS U24 CA194354
Abstract
Although immunotherapy has revolutionized cancer treatment, many patients still experience limited benefit, highlighting the urgent need for improved biomarkers
Indexed as
ImmunotherapyNeoplasmsThymus GlandAgedB7-H1 AntigenCarcinoma, Non-Small-Cell LungCohort StudiesDisease ProgressionFemaleHumansImmune Checkpoint InhibitorsLung NeoplasmsMaleMiddle AgedMutationProspective StudiesB7-H1 AntigenCD274 protein, humanImmune Checkpoint InhibitorsReceptors, Antigen, T-Cell
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.